New advances in treating non-small cell lung cancer
Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research at Yale Cancer Center, in December 2020 the FDA approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC
Herbst, MD, PhD, Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research at Yale Cancer Center, in December 2020 the FDA approved osimertinib for the treatment of adults with early-stage, non-small cell lung cancer (NSCLC